menu
    • menu
    [{"orgOrder":0,"company":"BioTheryX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"BTX-A51","moa":"CK1 alpha","graph1":"Oncology","graph2":"Phase I","graph3":"BioTheryX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioTheryX \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioTheryX \/ Not Applicable"},{"orgOrder":0,"company":"BioTheryX","sponsor":"MSD Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Series D Financing","leadProduct":"BTX-A51","moa":"Multi-Kinase","graph1":"Oncology","graph2":"Phase I","graph3":"BioTheryX","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"BioTheryX \/ MSD Partners","highestDevelopmentStatusID":"6","companyTruncated":"BioTheryX \/ MSD Partners"},{"orgOrder":0,"company":"BioTheryX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"BTX-1188","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"BioTheryX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioTheryX \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioTheryX \/ Not Applicable"},{"orgOrder":0,"company":"BioTheryX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BTX-1188","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"BioTheryX","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioTheryX \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioTheryX \/ Not Applicable"},{"orgOrder":0,"company":"BioTheryX","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"BioTheryX","amount2":0.35999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.35999999999999999,"dosageForm":"","sponsorNew":"BioTheryX \/ Incyte Corporation","highestDevelopmentStatusID":"2","companyTruncated":"BioTheryX \/ Incyte Corporation"},{"orgOrder":0,"company":"BioTheryX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"BTX-9341","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"BioTheryX","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BioTheryX \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioTheryX \/ Not Applicable"},{"orgOrder":0,"company":"BioTheryX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"BTX-9341","moa":"","graph1":"Technology","graph2":"Approved","graph3":"BioTheryX","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"BioTheryX \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioTheryX \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by BioTheryX

    Menu

    BioTheryX

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BioTheryX

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            BioTheryX

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BTX-9341,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Biotheryx Doses First Patient in Phase 1 Trial of BTX-9341 for HR+/HER2- Breast Cancer

                            Details : BTX-9341 is a first-in-class, oral degrader of cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6), being investigated in combination with Fulvestrant for HR+/HER- breast cancer.

                            Brand Name : BTX-9341

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 17, 2024

                            Lead Product(s) : BTX-9341,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BioTheryX

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            BioTheryX

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BTX-9341

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Biotheryx Announces FDA Clearance for BTX-9341, a First-In-Class Dual Degrader of CDK4/6

                            Details : BTX-9341 is a first-in-class, oral degrader of cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6), being investigated for HR+/HER- breast cancer.

                            Brand Name : BTX-9341

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 07, 2024

                            Lead Product(s) : BTX-9341

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BioTheryX

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            BioTheryX

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Incyte Corporation

                            Deal Size : $360.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Biotheryx Announces Research Collaboration and License Agreement with Incyte for Discovery of Targeted Protein...

                            Details : The Collaboration will leverage Biotheryx's PRODEGY platform to discover molecular glue degraders for multiple historically undruggable novel oncology targets.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : $7.0 million

                            April 05, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Incyte Corporation

                            Deal Size : $360.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BioTheryX

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            BioTheryX

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BTX-1188

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioTheryX Doses First Patient in Phase 1 Study Investigating Lead Protein Degrader Candidate BTX-1188

                            Details : BTX-1188, an oral, dual-target protein degrader demonstrated rapid, deep and durable degradation of both GSPT1 and IKZF1/3 at low nanomolar concentrations in the preclinical model in patients with Advanced Hematologic and Solid tumor malignancies.

                            Brand Name : BTX-1188

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 26, 2022

                            Lead Product(s) : BTX-1188

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            BioTheryX

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            BioTheryX

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BTX-1188

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioTheryX Receives IND Clearance from FDA to Proceed with Phase 1 Study of BTX-1188, a Molecular Glue, for the...

                            Details : BTX-1188 is a small molecule cereblon binder promotes the degradation of a neosubstrate G1 to S phase transition 1 (GSPT1), a translation termination factor, as well as IKZF1/3, zinc finger transcription factors important in hematological function.

                            Brand Name : BTX-1188

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 02, 2021

                            Lead Product(s) : BTX-1188

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            BioTheryX

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            BioTheryX

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BTX-A51

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : MSD Partners

                            Deal Size : $35.0 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            BioTheryX Announces $35 Million Series D Financing

                            Details : Proceeds from the financing will be used to accelerate the timeline of the BTX-A51 Phase 1 clinical trial through, continue IND-enabling studies for therapeutic candidates utilizing both PHMs™ and PHM®-based PROTACs and general corporate purposes.

                            Brand Name : BTX-A51

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 28, 2020

                            Lead Product(s) : BTX-A51

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : MSD Partners

                            Deal Size : $35.0 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            BioTheryX

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            BioTheryX

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BTX-A51

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioTheryX Announces the Initiation of Patient Dosing in a First-in-Man Phase 1 Clinical Trial of BTX-A51, a Mu...

                            Details : Study is evaluating the safety/tolerability of BTX-A51 in patients with relapsed/refractory acute myeloid leukemia (AML), as well as high risk myelodysplastic syndrome patients.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 16, 2020

                            Lead Product(s) : BTX-A51

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth